HLA Panel Reactive IgG Antibodies PRA Class I Quantitative Test
Comprehensive Introduction to HLA PRA Class I Testing
The HLA Panel Reactive IgG Antibodies PRA Class I Quantitative Test represents a cornerstone in modern transplant medicine, providing essential immunological assessment for patients awaiting organ transplantation. This sophisticated diagnostic tool measures the presence and concentration of IgG antibodies directed against Human Leukocyte Antigen (HLA) Class I molecules, which are critical cell surface proteins involved in immune recognition and rejection processes.
Understanding a patient’s HLA antibody profile is fundamental to successful transplantation outcomes. The test’s quantitative approach allows transplant teams to precisely gauge immunological risk and make informed decisions about donor compatibility, ultimately reducing the likelihood of antibody-mediated rejection and improving long-term graft survival.
What This Test Measures and Detects
The HLA PRA Class I Quantitative Test specifically identifies and quantifies IgG antibodies targeting HLA Class I antigens, which include HLA-A, HLA-B, and HLA-C molecules. These antigens are expressed on virtually all nucleated cells in the body and play a crucial role in immune system recognition of foreign tissues.
Key Measurements Include:
- Percentage of Panel Reactive Antibodies (PRA) against HLA Class I antigens
- Specific antibody strength and concentration levels
- Identification of antibody specificities against common HLA types
- Quantitative assessment of immunological sensitization
Using advanced Luminex X-Map technology, the test provides highly sensitive and specific detection of HLA antibodies, offering superior accuracy compared to traditional methods. This technology enables simultaneous testing against multiple HLA antigens, providing comprehensive antibody profiling.
Who Should Consider This Test
This specialized test is primarily indicated for patients in specific clinical scenarios related to transplantation and immunological assessment.
Primary Candidates Include:
- Patients awaiting kidney, heart, liver, lung, or pancreas transplantation
- Individuals with previous organ transplants experiencing potential rejection
- Patients with a history of blood transfusions, pregnancies, or previous transplants
- Those with autoimmune conditions affecting transplant eligibility
- Patients being evaluated for living donor transplantation
Clinical Indications:
- Pre-transplant immunological evaluation and risk assessment
- Monitoring antibody levels in sensitized patients
- Evaluation of potential transplant recipients with known immunological risk factors
- Assessment of desensitization therapy effectiveness
Significant Benefits of HLA PRA Testing
Undergoing HLA Panel Reactive Antibodies testing provides numerous advantages for both patients and transplant teams, contributing to improved transplantation outcomes and patient safety.
Key Benefits Include:
- Enhanced Transplant Success: Identifies compatible donors and reduces rejection risk
- Personalized Treatment Planning: Guides immunosuppression strategies based on individual antibody profiles
- Reduced Waiting Times: Helps identify suitable donors more efficiently through virtual crossmatching
- Improved Patient Safety: Prevents hyperacute rejection by detecting pre-formed antibodies
- Comprehensive Risk Assessment: Provides quantitative data for informed clinical decision-making
Understanding Your Test Results
Interpreting HLA PRA Class I results requires specialized medical expertise, but understanding the general principles can help patients participate more actively in their care.
Result Interpretation Guidelines:
- Low PRA (0-10%): Indicates minimal sensitization and broader donor compatibility
- Moderate PRA (11-79%): Suggests some immunological sensitization requiring careful donor matching
- High PRA (80-100%): Significant sensitization that may require desensitization therapy or specialized matching protocols
Your transplant physician will discuss your specific results in detail, explaining how they impact your transplant options and treatment plan. The quantitative nature of this test provides precise information about antibody strength, which helps guide the intensity of immunosuppressive therapy and donor selection criteria.
Test Pricing and Availability
| Test Name | Discount Price | Regular Price |
|---|---|---|
| HLA Panel Reactive IgG Antibodies PRA Class I Quantitative Test | $376 USD | $550 USD |
Test Details:
- Turnaround Time: 10-12 days
- Sample Type: 3 mL (1.5 mL minimum) serum from 1 SST
- Shipping Requirements: Ship refrigerated or frozen
- Special Instructions: Collect specimen preferably 48 hours after dialysis. Provide brief clinical history.
Nationwide Availability and Booking
General Genetics Corporation provides comprehensive HLA testing services across the United States, with convenient locations in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our state-of-the-art laboratories ensure accurate and timely results for transplant candidates nationwide.
Take the next step toward your transplantation journey with confidence. Our experienced team is ready to assist you with scheduling, sample collection, and result interpretation.
Ready to Schedule Your Test?
Contact our transplant testing specialists today to book your HLA PRA Class I Quantitative Test and take control of your transplant evaluation process.
Call or WhatsApp: +1(267) 388-9828
Available: Monday – Friday, 8:00 AM – 6:00 PM EST
Our dedicated team understands the importance of timely and accurate HLA testing in the transplant evaluation process. We work closely with transplant centers nationwide to ensure seamless integration of test results into your medical care plan, providing the critical immunological information needed for successful transplantation outcomes.
